Questions we get, answered plainly.
No. GLP-III is a non-drug dietary supplement. It contains no semaglutide, tirzepatide, or any peptide GLP-1 receptor agonist, and it is not a substitute for prescribed therapy.
It refers to design scope: the formulation is built to support signaling across three receptor families — GLP-1R, GIP-R, and GCG-R — rather than targeting one in isolation.
A crystalline lattice with tunable pore geometry. We are developing it to hold actives through gastric transit and release them on a pH and enzymatic cue rather than on a timer. It is a separate research track — the filings cover the carrier platform, and GLP-III does not use it.
No. The two are independent. GLP-III is a triple-receptor formulation with its own patent-pending filing; the MOF carrier platform is earlier-stage research that has not shipped in any product.
It is pre-launch. Join the notify list and you will hear on the day it ships — no earlier marketing sequence.
No. Book One makes no product claims and does not mention GLP-III formulations. That separation is deliberate and part of our review standard.
The Education Hub is not a journal. Articles cite primary literature and are reviewed internally against those sources; where evidence is contested, the article says so in the body.
Get the mechanism, not the marketing.
Launch dates, new articles, and Book Two progress. Roughly monthly, no drip sequences.
We send launch notices and new articles. No drip sequences.